Merck (MRK) CMD 2024 summary

Strategic and operational highlights

• Confirmed return to growth in 2024, with all three business sectors—Life Science, Healthcare, and Electronics—showing positive momentum and raised group guidance for the year.

• Life Science expects a solid exit rate in 2024, bridging to midterm ambitions, with Process Solutions forecasted for 7%-9% organic growth, outpacing the market by 200 basis points; post-COVID growth is driven by bioprocessing and improved order intake.

• Healthcare leverages a resilient portfolio, with growth from established franchises and recent launches, aiming for mid-single-digit growth long term, supported by a more de-risked pipeline and external innovation; key drivers include CM&E, Fertility, Mavenclad, and Erbitux.

• Electronics benefits from AI-driven demand and advanced nodes, raising its midterm sales growth target to 5%-9%, with semiconductors now 80% of the portfolio and growth propelled by recovery in memory and analog nodes.

• Portfolio transformation includes the divestment of Surface Solutions, acquisitions in bioprocessing (Mirus) and AI (UnitySC), and a focus on innovation and sustainability.

Financial guidance and capital allocation

• 2024 guidance reconfirmed: sales of €20.7–22.1 billion, EBITDA pre of €5.8–6.4 billion, and EPS pre of €8.20–9.30; organic sales growth guidance for 2024 is +2% to +5%.

• All sectors expected to drive organic growth in H2 2024, with Process Solutions and Electronics showing sequential improvement.

• CapEx intensity to decrease after 2025 as major capacity expansions complete, with 2024 capex guidance of €1.6–1.8bn, enhancing free cash flow and funding M&A ambitions.

• M&A focus remains on Life Science, with disciplined approach and strict financial criteria; Healthcare targets in-licensing and low-risk bolt-ons, while Electronics prioritizes internal innovation and bolt-on technology acquisitions.

• Historical value creation: 8% CAGR in sales and 12% CAGR in EPS over 15 years, with 550% total shareholder return, outperforming major indices; 5% organic sales CAGR and 10% EBITDA pre CAGR from FY09–23.

Innovation, sustainability, and ESG

• Innovation is central, with leadership in ADCs, DNA damage response inhibitors, next-gen thin film technologies, and digitalization driving product and operational advances.

• Sustainability targets exceeded for water and waste reduction in 2023; new 2030 goals include 50% water intensity improvement and 70% circularity rate, with a commitment to climate neutrality by 2040.

• Over 2,500 sustainable products developed in Life Science, a 30% increase since 2020; circular economy initiatives and supplier decarbonization programs underway.

• DE&I progress includes 39% women in leadership, 100% fertility benefit coverage, and new inclusive leadership workshops; health equity initiatives target access and clinical trial diversity.

• ESG leadership recognized by customers and peers, with digital tools enabling customer sustainability dashboards and data-driven product carbon footprinting.